DaVita (NYSE:DVA) Cut to Strong Sell at Zacks Research

Zacks Research downgraded shares of DaVita (NYSE:DVA) from a hold rating to a strong sell rating in a report published on Thursday,Zacks.com reports.

A number of other analysts have also recently weighed in on DVA. Wall Street Zen cut shares of DaVita from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of DaVita in a report on Wednesday, October 8th. Truist Financial set a $140.00 price objective on DaVita in a report on Tuesday, October 14th. Bank of America dropped their price objective on DaVita from $145.00 to $140.00 and set an “underperform” rating on the stock in a report on Wednesday, September 10th. Finally, Barclays dropped their price objective on DaVita from $149.00 to $143.00 and set an “equal weight” rating on the stock in a report on Thursday. Four research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, DaVita currently has a consensus rating of “Reduce” and an average target price of $151.75.

DaVita Stock Up 0.1%

NYSE:DVA opened at $118.84 on Thursday. The stock’s fifty day moving average is $130.78 and its two-hundred day moving average is $136.60. DaVita has a 52 week low of $115.39 and a 52 week high of $179.60. The stock has a market capitalization of $8.50 billion, a price-to-earnings ratio of 12.24, a price-to-earnings-growth ratio of 0.91 and a beta of 1.13.

DaVita (NYSE:DVA) last released its earnings results on Wednesday, October 29th. The company reported $2.51 earnings per share for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.66). DaVita had a return on equity of 815.62% and a net margin of 5.80%.The firm had revenue of $3.42 billion for the quarter, compared to analysts’ expectations of $3.43 billion. During the same quarter in the previous year, the company posted $2.59 earnings per share. The firm’s quarterly revenue was up 4.8% on a year-over-year basis. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. On average, sell-side analysts expect that DaVita will post 10.76 EPS for the current fiscal year.

Institutional Investors Weigh In On DaVita

Large investors have recently made changes to their positions in the company. National Pension Service increased its stake in shares of DaVita by 74.3% in the first quarter. National Pension Service now owns 197 shares of the company’s stock valued at $30,000 after purchasing an additional 84 shares during the period. Hantz Financial Services Inc. boosted its holdings in shares of DaVita by 48.1% in the second quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock valued at $33,000 after acquiring an additional 75 shares in the last quarter. Y.D. More Investments Ltd bought a new position in shares of DaVita in the first quarter valued at approximately $35,000. Mid American Wealth Advisory Group Inc. bought a new position in shares of DaVita in the second quarter valued at approximately $36,000. Finally, Canada Pension Plan Investment Board bought a new position in shares of DaVita in the second quarter valued at approximately $43,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.